A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus

NCT03866317 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Difficulty recruiting participants

Conditions

Discoid Lupus Erythematosus

Interventions

DRUG: Secukinumab

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]